Clinical significance of MET in gastric cancer

doi:10.4251/wjgo.v7.i11.317

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8142)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

588

WORD

293

HTML

4651

Tables (1-4)

151

Sum=5683

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1073

Download

1386

Sum=2459

Nov 15, 2015 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (32)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastrointest Oncol. Nov 15, 2015; 7(11): 317-327
Published online Nov 15, 2015. doi: 10.4251/wjgo.v7.i11.317

Table 4 Development of MET-targeting agents for gastric cancer

Type	Agent	Other targets	Phase	Line	Combined therapy	Results or status	Ref.
MET selective	Tivantinib (ARQ197)	None	II	2^nd/3^rd	None	No CR/PR	[72]
non-ATP competitive TKI	Tivantinib (ARQ197)	None	II	2^nd/3^rd	None	Median PFS 1.4 mo	[72]
MET-selective	AMG 337	None	II	Any	None	Ongoing	[74]
ATP-competitive TKI			I	2^nd/3^rd	None	1 CR and 4 PR in 10 patients with MET -amplified tumor	[73]
Multitargeted	Foretinib	VEGFR2, RON, AXL, TIE2	II	1^st (95%)	Docetaxel, Cisplatin	No CR/PR	[75]
ATP-competitive TKI	(GSK1363089)	VEGFR2, RON, AXL, TIE2	II	1^st (95%)	Docetaxel, Cisplatin	Median OS 7.4	[75]
	Crizotinib	ALK	I			Tumor shrinkage in 2 patients with PFS 3.5 and 3.7 mo	[39]
	(PF-2341066)	ALK	I			Tumor shrinkage in 2 patients with PFS 3.5 and 3.7 mo	[39]
MET mAb	Onartuzumab (MetMab )	None	III	1^st	mFOLFOX	Ongoing	[77]
HGF mAb	Rilotumumab	None	III	1^st	ECX	Suspended	[79]
	(AMG 102)	None	III	1^st	CX	Suspended	[80]
		None	II	1^st	ECX	Median PFS 4.2 mo	[78]
		None	II	1^st	ECX	Median OS 5.6 mo	[78]

ATP: Adenosine triphosphate; TKI: Tyrosine kinase inhibitor; mAb: Monoclonal antibody; VEGFR: Vascular endothelial growth factor receptor; ALK: Anaplastic lymphoma kinase; TIE: Tunica internal endothelial cell kinase; CR: Complete response; PR: Partial response; RFS: Relapse-free survival; OS: Overall survival; FOLFOX: Folinic acid + fluorouracil + oxaliplatin; ECX: Epirubicin + oxaliplatin + capecitabine; CX: Oxaliplatin + capecitabine.

Citation: Inokuchi M, Otsuki S, Fujimori Y, Sato Y, Nakagawa M, Kojima K. Clinical significance of MET in gastric cancer. World J Gastrointest Oncol 2015; 7(11): 317-327
URL: https://www.wjgnet.com/1948-5204/full/v7/i11/317.htm
DOI: https://dx.doi.org/10.4251/wjgo.v7.i11.317